Immix Biopharma Inc (IMMX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.50 (-1.73%), Market cap $0.54B, 52-week low–high $1.95 ~ $11.12.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Financial statements, price targets, institutional (13F) holdings and related news for Immix Biopharma Inc are updated in real time on BlackAll Trade.
Immix Biopharma Inc trades at $12.50 (-1.73%). Real-time quotes and charts are available on BlackAll Trade.
Immix Biopharma Inc has a market cap of about $0.54B.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the U